New heads of prime brokerage and listed derivatives at UBS

Stuart Hendel and Mitch Moore have joined UBS as global head of prime brokerage and global head of exchange-traded derivatives, respectively.

Both new recruits will join the Swiss bank at the beginning of September, reporting to Daniel Coleman, the global head of equities. Hendel will be based in New York and Moore will be based in London.

Before joining UBS, Hendel had two spells at Morgan Stanley in New York, separated by a three-year stint between 2004 and 2007 at hedge fund Eton Park Capital Management, where he was chief operating officer. He replaces Alex Ehrlich, who has moved to Morgan Stanley as global head of prime brokerage - Hendel's former post.

Moore was at UBS from 1992 until stepping down temporarily last year. His most recent role at the bank, which he held until March 2008, was global chief operating officer for equities and fixed income, currencies and commodities. Moore has also held other senior positions at the firm, including global head of prime brokerage and global head of convertible sales. He previously ran the exchange-traded derivatives business for UBS and its predecessor firm, Union Bank of Switzerland.

Moore replaces Clark Hutchison and Bill Templer, the bank's former co-heads of exchange-traded derivatives, who will join Morgan Stanley in September as co-heads of listed derivatives. Before Moore's appointment, Coleman, together with regional heads Reinhardt Olsen (US), Tim Woodward (Europe, the Middle East and Africa) and David Gray (Asia-Pacific), took interim responsibility for UBS's exchange-traded derivatives business.

See also: New heads of global listed derivatives for Morgan Stanley

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@risk.net or view our subscription options here: http://subscriptions.risk.net/subscribe

You are currently unable to copy this content. Please contact info@risk.net to find out more.

Most read articles loading...

You need to sign in to use this feature. If you don’t have a Risk.net account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here